Clinical trials: Huntington's Disease
Huntington Disease
Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD
A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.
- Trial name
- Chol-HD (NCT04257513)
- Testing
- Brain MRI
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Huntington's Disease (HD)
Creatine Safety & Tolerability in Huntington's Disease
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
- Trial name
- CREST-X (NCT01412151)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of…
- Trial name
- NCT07516899
- Testing
- [14C] LPM3770164
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
- Trial name
- NCT06585449
- Testing
- ALN-HTT02
- Where
- 19 sites in Canada, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Huntington Disease
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
The researchers hope to find out effects of transcranial direct current stimulation (tDCS) sessions on the behavioral symptoms of Huntington's Disease.
- Trial name
- NCT06843252
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Huntington Disease
A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278
The study drug, GSK356278, is a possible new medicine for the treatment of Huntington's disease. Huntington's disease, which is often called HD, is caused by a faulty gene that is passed down through families.
- Trial name
- NCT01573819
- Testing
- GSK356278
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease, Huntington's Disease
A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
This study is to characterize the pharmacokinetics of single and multiple oral doses of Dimebon in Japanese healthy subjects. This study is also to evaluate the safety and tolerability of single and multiple oral doses of Dimebon…
- Trial name
- NCT00825084
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington's Disease
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
This study will examine whether lithium carbonate, given alone or with divalproex, increases the amount of brain-derived neurotrophic factor (BDNF) in the spinal fluid of patients with Huntington's disease (HD), a hereditary…
- Trial name
- NCT00095355
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Huntington Disease
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
This is a prospective investigation which aims to address key challenges to the design of clinical trials to prevent the onset of Huntington's disease (HD).
- Trial name
- PREVENT-HD (NCT04818060)
- Testing
- Clinical Assessments, MRI Scan, Lumber Puncture (LP)
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Huntington's Disease
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
- Trial name
- NCT01806896
- Testing
- PF-02545920
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Pfizer
Health Volunteers, Huntington Disease
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted
- Trial name
- NCT03019289
- Testing
- pridopidine (90 mg)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Prilenia
Apathy, Huntington's Disease
Apathy Cure Through Bupropion in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in…
- Trial name
- Action-HD (NCT01914965)
- Testing
- Bupropion
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Huntington Disease
Cooperative Huntington's Observational Research Trial
The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in…
- Trial name
- NCT00313495
- Where
- 52 sites in United States, Australia and 1 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- HP Therapeutics Foundation
Huntington's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
- Trial name
- NCT02519036
- Testing
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Alzheimer's Disease, Huntington's Disease
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects.
- Trial name
- NCT00827034
- Testing
- Warfarin, Dimebon
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
- Trial name
- NCT05107128
- Testing
- SAGE-718
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 189 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Riluzole in Huntington's Disease
Primary objective: The primary objective of the study is to establish that riluzole slows down (1) the decrease in total functional capacity (TFC), (2) the increase of the motor score of the Unified Huntington's Disease Rating…
- Trial name
- NCT00277602
- Testing
- Riluzole
- Volunteers
- 537 people
- Sponsor
- Sanofi
Caregiver of Huntington's Disease Patient
Caregiver Burden in Huntington's Disease
Huntington's disease (HD) is a rare inherited neurodegenerative disorder, progressing between 15 and 20 years and affecting one person out of 10.000.
- Trial name
- PHRI-HD (NCT02876445)
- Testing
- ZARIT Burden Interview
- Where
- France
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
N- Homocysteinylated Huntingtin in Huntington's Disease
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts: 1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin), 2.
- Trial name
- HO-HD (NCT05225051)
- Testing
- skin biopsy
- Volunteers
- 32 people
- Sponsor
- Central Hospital, Nancy, France